Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Below 200 Day Moving Average – Time to Sell?
by Tristan Rich · The Markets DailyNorthwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.21 and traded as low as $0.1631. Northwest Biotherapeutics shares last traded at $0.1696, with a volume of 3,194,485 shares traded.
Northwest Biotherapeutics Trading Down 1.0%
The firm has a market capitalization of $286.30 million, a P/E ratio of -0.01 and a beta of -0.60. The stock has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.21.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.01) earnings per share for the quarter. The firm had revenue of $0.81 million for the quarter.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC acquired a new stake in shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned 0.07% of Northwest Biotherapeutics at the end of the most recent reporting period. Institutional investors own 0.04% of the company’s stock.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.